Actinogen Medical Limited
OTC: ATGGF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven G. Gourlay
- Employees
- 6
- Headquarters
- Sydney, Australia
- IPO year
- 2018
- Market cap
- $2.9M
- Website
- https://www.actinogen.com.au
Loading ATGGF…
Loading profile data…Frequently asked questions about ATGGF
What does Actinogen Medical Limited (ATGGF) do?
Actinogen Medical Limited is an Australian biotechnology firm specializing in the creation of treatments for neurological and neuropsychiatric conditions linked to abnormal brain cortisol levels. Their primary therapeutic candidate, Xanamem, functions as an inhibitor of the 11ß-HSD1 enzyme. Currently in Phase 2 clinical trials, Xanamem has shown...
Where does ATGGF trade?
Actinogen Medical Limited (ATGGF) trades on the Other OTC.
What sector is ATGGF in?
Actinogen Medical Limited (ATGGF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Actinogen Medical Limited?
Steven G. Gourlay is the chief executive officer of Actinogen Medical Limited (ATGGF).
Where is Actinogen Medical Limited headquartered?
Actinogen Medical Limited is headquartered in Australia.
Does ATGGF pay a dividend?
Actinogen Medical Limited (ATGGF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ATGGF go public?
Actinogen Medical Limited (ATGGF) completed its initial public offering in 2018.